#Hong Kong #Semaglutide #Ascletis #ASC47

Ascletis Reveals Groundbreaking Results for ASC47 in Obesity Treatment

Ascletis Pharma Inc., a biotechnology company based in Hong Kong, has reported promising clinical data on its new weight loss drug candidate, ASC47, when used in combination with semaglutide. This innovative approach has demonstrated up to a 56.2% greater relative reduction in body weight in participants suffering from obesity, in comparison to those receiving semaglutide alone. This pivotal study offers new insights into the management of obesity, a condition affecting a significant portion of the global population.

Study Overview

The ASC47-103 study, conducted in a randomized, double-blind, placebo-controlled format across the United States, included 28 participants diagnosed with obesity (having a body mass index of 30 kg/m² or greater). Over a four-week treatment duration, participants were administered an ultra-long-acting injectable formulation of ASC47 alongside semaglutide, with a follow-up period extending for six weeks. The study aimed to evaluate safety, tolerability, and efficacy, focusing on weight loss and changes in body composition.

Key Findings

The results highlight significant weight loss benefits from the ASC47 and semaglutide combination. On day 29 of the study, participants who received a single 30 mg dose of ASC47 alongside four doses of semaglutide showed a substantial 56.2% higher relative weight reduction compared to those on semaglutide monotherapy. Moreover, a 60 mg dose of ASC47 still indicated a notable 15.1% greater weight loss.

In contrast, the semaglutide monotherapy group recorded only a 2.5% weight reduction from baseline, underscoring the enhanced efficacy of adding ASC47. Interestingly, the 10 mg dose of ASC47 did not yield additional weight loss compared to the monotherapy, suggesting that effective dosage is critical for optimal results.

Another major advantage notable in the findings is the improved gastrointestinal tolerance. While the ASC47 combination group reported only 6.7% incidence of vomiting, a striking 57.1% of participants in the semaglutide monotherapy group experienced this side effect. Such gastrointestinal concerns are among the leading causes of therapy discontinuation in obesity treatments, making this revelation particularly significant.

Long-term Effects and Maintenance Therapy

Further follow-up data indicates that the ultra-long-acting formulation of ASC47 may serve as a valuable maintenance therapy. On day 57, participants who had previously received ASC47 showed a 157.1% greater relative reduction in body weight compared to the original semaglutide group. This resilience against weight regain post-treatment is crucial for patients looking for sustainable weight management solutions.

Safety and Tolerability Profile

The ASC47 in combination with semaglutide has shown a favorable safety profile, with no serious adverse events recorded during the study. The overall incidence of treatment-emergent adverse events (TEAEs) was comparable across all groups, and the profile for gastrointestinal events was notably improved. Thyroid function tests conducted during the study also showed normal limits, without any thyroid-related TEAEs reported.

Future Directions

Given these encouraging outcomes, Ascletis is now looking to advance its research with Phase IIb combination studies that may involve not only ASC47 but also ASC35, a GLP-1R/GIPR peptide agonist. These investigations will continue to illuminate the potential of ASC47 in addressing not just obesity, but also related metabolic disorders such as metabolic dysfunction-associated steatohepatitis (MASH).

As we await further developments, the initial findings position ASC47 as a promising contender in the obesity treatment landscape, potentially providing hope to millions struggling with this chronic condition. Stay tuned for more updates from Ascletis as they navigate the exciting realm of metabolic disease therapeutics.